Non-coding RNAs in cardiac hypertrophy

Journal of Physiology

Volumn 595, Issue 12, 2017, Pages 4037-4050

  Ottaviani, Lara ^a   da Costa Martins, Paula A ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b University of Porto   (Portugal)

Author keywords

heart failure; hypertrophy; intracellular communication; non coding RNA

Indexed keywords

BRAVEHEART; CARDIAC APOPTOSIS RELATED; CARDIAC HYPERTROPHY ASSOCIATED TRANSCRIPT; CARDIAC HYPERTROPHY RELATED FACTOR; FOXF1 ADJACENT NON CODING DEVELOPMENTAL REGULATORY RNA; HEART RELATED CIRCULAR RNA; MICRORNA 1; MICRORNA 132; MICRORNA 133; MICRORNA 181C; MICRORNA 195; MICRORNA 199A; MICRORNA 208; MICRORNA 208A; MICRORNA 21; MICRORNA 210; MICRORNA 212; MICRORNA 214; MICRORNA 22; MICRORNA 27A; MICRORNA 27B; MICRORNA 29; MICRORNA 29B; MICRORNA 378; MICRORNA 499; MICRORNA 696; MICRORNA 98; MYOSIN HEAVY CHAIN ASSOCIATED RNA TRANSCRIPT; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNTRANSLATED RNA;

CELL COMMUNICATION; CELL TRANSFER; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UPREGULATION; ANIMAL; CARDIOMEGALY; DISEASE EXACERBATION; GENETICS; PATHOLOGY; PROGNOSIS;

ANIMALS; CARDIOMEGALY; DISEASE PROGRESSION; HEART FAILURE; HUMANS; PROGNOSIS; RNA, UNTRANSLATED;

EID: 85018917707     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP273129     Document Type: Review

References (92)

1. Abonnenc M, Nabeebaccus AA, Mayr U, Barallobre-Barreiro J, Dong X, Cuello F, Sur S, Drozdov I, Langley SR, Lu R, Stathopoulou K, Didangelos A, Yin X, Zimmermann WH, Shah AM, Zampetaki A & Mayr M (2013). Extracellular matrix secretion by cardiac fibroblasts: Role of MicroRNA-29b and MicroRNA-30c. Circ Res 113, 1138–1147.
2. Aoi W, Naito Y, Mizushima K, Takanami Y, Kawai Y, Ichikawa H & Yoshikawa T (2010). The microRNA miR-696 regulates PGC-1α in mouse skeletal muscle in response to physical activity. Am J Physiol Endocrinol Metab 298, E799–E806.
3. Archer K, Broskova Z, Bayoumi AS, Teoh JP, Davila A, Tang Y, Su H & Kim IM (2015). Long non-coding RNAs as master regulators in cardiovascular diseases. Int J Mol Sci 16, 23651–23667.
4. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, Evantal N, Memczak S, Rajewsky N & Kadener S (2014). CircRNA Biogenesis competes with Pre-mRNA splicing. Mol Cell 56, 55–66.
5. Azzouzi H el, Leptidis S, Doevendans PA & De Windt LJ (2015). HypoxamiRs: regulators of cardiac hypoxia and energy metabolism. Trends Endocrinol Metab 26, 502–508.
6. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K, Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y, Schober A, Fiedler J & Thum T (2014). Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124, 2136–2146.
7. Bartel DP (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
8. Bejerano G, Pheasant M, Makunin I, Stephen S, Kent WJ, Mattick JS & Haussler D (2004). Ultraconserved elements in the human genome. Science 304, 1321–1325.
9. De Boer RA, Pinto YM & Van Veldhuisen DJ (2003). The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation 10, 113–126.
10. Callis TE, Pandya K, Hee YS, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, Willis MS, Selzman CH & Wang DZ (2009). MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119, 2772–2786.
11. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C & Condorelli G (2007). MicroRNA-133 controls cardiac hypertrophy. Nat Med 13, 613–618.
12. Castaldi A, Zaglia T, Di Mauro V, Carullo P, Viggiani G, Borile G, Di Stefano B, Schiattarella GG, Gualazzi MG, Elia L, Stirparo GG, Colorito ML, Pironti G, Kunderfranco P, Esposito G, Bang ML, Mongillo M, Condorelli G & Catalucci D (2014). MicroRNA-133 modulates theβ1-adrenergic receptor transduction cascade. Circ Res 115, 273–283.
13. Cech TR & Steitz JA (2014). The noncoding RNA revolution – trashing old rules to forge new ones. Cell 157, 77–94.
14. Chan YC, Banerjee J, Choi SY & Sen CK (2012). miR-210: The master hypoxamir. Microcirculation 19, 215–223.
15. Chen L (2016). The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol 17, 205–211.
16. 2-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 47, 5–14.
17. Climent M, Quintavalle M, Miragoli M, Chen J, Condorelli G & Elia L (2015). TGFβ triggers miR-143/145 transfer from smooth muscle cells to endothelial cells, thereby modulating vessel stabilization. Circ Res 116, 1753–1764.
18. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S & Schroen B (2010). Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3, 499–506.
19. da Costa Martins PA, Salic K, Gladka MM, Armand A-S, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T & De Windt LJ (2010). MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signaling. Nat Cell Biol 12, 1220–1227.
20. Das S, Bedja D, Campbell N, Dunkerly B, Chenna V, Maitra A & Steenbergen C (2014). miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One 9, e96820.
21. Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, Stuhrmann M, Givens RC, Kennel PJ, Christian Schulze P, Widder JD, Bauersachs J & Thum T (2015). Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol 196, 115–122.
22. Devaux Y, Zangrando J, Schroen B, Creemers EE, Pedrazzini T, Chang C-P, Dorn GW, Thum T & Heymans S (2015). Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol 12, 415–425.
23. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, vanderMade I, Herias V, vanLeeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM & Creemers EE (2009). miR-133and miR-30 regulate connective tissue growth factor: implications for a role of micrornas in myocardial matrix remodelling. Circ Res 104, 170–178.
24. EL Andaloussi SE, Mäger I, Breakefield XO & Wood MJ (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12, 347–357.
25. El Azzouzi H, Leptidis S, Dirkx E, Hoeks J, van Bree B, Brand K, McClellan EA, Poels E, Sluimer JC, van den Hoogenhof MM, Armand AS, Yin X, Langley S, Bourajjaj M, Olieslagers S, Krishnan J, Vooijs M, Kurihara H, Stubbs A, Pinto YM, Krek W, Mayr M, da Costa Martins PA, Schrauwen P & De Windt LJ (2013). The hypoxia-inducible microRNA cluster miR-199a∼214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation. Cell Metab 18, 341–354.
26. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D & Condorelli G (2009). Reciprocal regulation of microrna-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120, 2377–2385.
27. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon VB, Brija T, Gautier EL, Ivanov S, Satpathy AT, Schilling JD, Schwendener R, Sergin I, Razani B, Forsberg EC, Yokoyama WM, Unanue ER, Colonna M, Randolph GJ & Mann DL (2014). Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40, 91–104.
28. Friese RS Altshuler AE, Zhang K, Miramontes-Gonzalez JP, Hightower CM, Jirout ML, Salem RM, Gayen JR, Mahapatra NR, Biswas N, Cale M, Vaingankar SM, Kim HS, Courel M, Taupenot L, Ziegler MG, Schork NJ, Pravenec M, Mahata SK, Schmid-Schönbein GW & O'Connor DT (2013). MicroRNA-22 and promoter motif polymorphisms at the Chga locus in genetic hypertension: Functional and therapeutic implications for gene expressionand the pathogenesis of hypertension. Hum Mol Genet 22, 3624–3640.
29. Garcia NA, Ontoria-Oviedo I, González-King H, Diez-Juan A & Sepúlveda P (2015). Glucose starvation in cardiomyocytes enhances exosome secretion and promotes angiogenesis in endothelial cells. PLoS One 10, e0138849.
30. Ghildiyal M & Zamore PD (2009). Small silencing RNAs: an expanding universe. Nat Rev Genet 10, 94–108.
31. Grote P, Wittler L, Hendrix D, Koch F, Währisch S, Beisaw A, Macura K, Bläss G, Kellis M, Werber M & Herrmann BG (2013). The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell 24, 206–214.
32. Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, Van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee B, Kelm RJ, Reddy AK, Taffet GE, Bradley A, Wehrens XH, Entman ML & Rodriguez A (2012). Targeted deletion of MicroRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 125, 2751–2761.
33. Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQN, Scherr M, Castermans K, Malvaux L, Lambert V, Thiry M, Sliwa K, Noel A, Martial JA, Hilfiker-Kleiner D & Struman I (2013). MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 123, 2143–2154.
34. Han P, Hang CT, Yang J & Chang CP (2011). Chromatin remodelling in cardiovascular development and physiology. Circ Res 108, 378–396.
35. Han P, Li W, Lin C-H, Yang J, Shang C, Nurnberg ST, Jin KK, Xu W, Lin C-Y, Lin C-J, Xiong Y, Chien H-C, Zhou B, Ashley E, Bernstein D, Chen P-S, Chen H-SV, Quertermous T & Chang C-P (2014). A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102–106.
36. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK & Kjems J (2013). Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388.
37. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E, Janssen BJ, Creemers EE, Pinto YM, Grimm D, Schürmann N, Vigorito E, Thum T, Stassen F, Yin X, Mayr M, de Windt LJ, Lutgens E, Wouters K, de Winther MP, Zacchigna S, Giacca M, van Bilsen M, Papageorgiou AP & Schroen B (2013). Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation 128, 1420–1432.
38. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC & Wu JC (2010). MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122 (Suppl.), S124–131.
39. Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X & Wang DZ (2013). MicroRNA-22 regulates cardiac hypertrophy and remodelling in response to stress. Circ Res 112, 1234–1243.
40. Jentzsch C, Leierseder S, Loyer X, Flohrschütz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B & Engelhardt S (2012). A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 52, 13–20.
41. Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ & Lebeche D (2013). Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodelling. J Am Heart Assoc 2, e000078.
42. Kehat I & Molkentin JD (2010). Molecular pathways underlying cardiac remodelling during pathophysiological stimulation. Circulation 122, 2727–2735.
43. Khan MAF, Reckman YJ, Aufiero S, van den Hoogenhof MMGG, van der Made I, Beqqali A, Koolbergen DR, Rasmussen TB, van der Velden J, Creemers EE & Pinto YM (2016). RBM20 regulates circular RNA production from the Titin gene. Circ Res 119, 996–1003.
44. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, Ding H, Butty VL, Torrey L, Haas S, Abo R, Tabebordbar M, Lee RT, Burge CB & Boyer LA (2013). Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell 152, 570–583.
45. Kleinjan DA & Van Heyningen V (2005). Long-range control of gene expression: emerging mechanisms and disruption in disease. Am J Hum Genet 76, 8–32.
46. Knezevic I, Patel A, Sundaresan NR, Gupta MPM, Solaro RJ, Nagalingam RS & Gupta MPM (2012). A novel cardiomyocyte-enriched MicroRNA, miR-378, targets insulin-like growth factor 1 receptor: Implications in postnatal cardiac remodelling and cell survival. J Biol Chem 287, 12913–12926.
47. Konstam MA, Kramer DG, Patel AR, Maron MS & Udelson JE (2011). Left ventricular remodelling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4, 98–108.
48. Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y & Xiao X (2011). Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res 109, 1332–1341.
49. Leptidis S, el Azzouzi H, Lok SI, de Weger R, Olieslagers S, Kisters N, Silva GJ, Heymans S, Cuppen E, Berezikov E, de Windt LJ & da Costa Martins P (2013). A Deep sequencing approach to uncover the miRNOME in the human heart. PLoS One 8, e57800.
50. Lips DJ, DeWindt LJ, Van Kraaij DJW & Doevendans PA (2003). Molecular determinants of myocardial hypertrophy and failure: Alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J 24, 883–896.
51. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH, Dorn LE, Watson MA, Margulies KB & Dorn GW (2009). Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 119, 1263–1271.
52. Matkovich SJ, Edwards JR, Grossenheider TC, de Guzman Strong C & Dorn GW (2014). Epigenetic coordination of embryonic heart transcription by dynamically regulated long noncoding RNAs. Proc Natl Acad Sci USA 111, 12264–12269.
53. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE & Dorn GW (2012). Direct and indirect involvement of MicroRNA-499 in clinical and experimental cardiomyopathy. Circ Res 111, 521–531.
54. Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM & Dorn GW (2010). MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106, 166–175.
55. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F & Rajewsky N (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338.
56. Nakagawa S (2016). Lessons from reverse-genetic studies of lncRNAs. Biochim Biophys Acta 1859, 177–183.
57. Papageorgiou N, Tsalamandris S, Giolis A & Tousoulis D (2015). MicroRNAs in cardiovascular disease: perspectives and reality. Cardiol Rev 24, 110–118.
58. Patrick DM, Montgomery RL, Qi X, Obad S, Kauppinen S, Hill JA, Van Rooij E & Olson EN (2010). Stress-dependent cardiac remodelling occurs in the absence of microRNA-21 in mice. J Clin Invest 120, 3912–3916.
59. Pennacchio LA, Ahituv N, Moses AM, Prabhakar S, Nobrega MA, Shoukry M, Minovitsky S, Dubchak I, Holt A, Lewis KD, Plajzer-Frick I, Akiyama J, De Val S, Afzal V, Black BL, Couronne O, Eisen MB, Visel A & Rubin EM (2006). In vivo enhancer analysis of human conserved non-coding sequences. Nature 444, 499–502.
60. Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K & Li H (2015). Circular RNA: A new star of noncoding RNAs. Cancer Lett 365, 141–148.
61. Roncarati R, Viviani Anselmi C, Losi MA, Papa L, Cavarretta E, Da Costa Martins P, Contaldi C, Saccani Jotti G, Franzone A, Galastri L, Latronico MVG, Imbriaco M, Esposito G, De Windt L, Betocchi S & Condorelli G (2014). Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 63, 920–927.
62. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA & Olson EN (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103, 18255–18260.
63. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J & Olson EN (2007). Control of stress-dependent cardiac growth and gene expression by a microRNA. Science (80-) 316, 575–579.
64. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA & Olson EN (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105, 13027–13032.
65. Salomon C, Ryan J, Sobrevia L, Kobayashi M, Ashman K, Mitchell M & Rice GE (2013). Exosomal signaling during hypoxia mediates microvascular endothelial cell migration and vasculogenesis. PLoS One 8, e68451.
66. Salzman J (2016). Circular RNA expression: Its Potential regulation and function. Trends Genet 32, 309–316.
67. Salzman J, Chen RE, Olsen MN, Wang PL & Brown PO (2013). Cell-type specific features of circular RNA expression. PLoS Genet 9, e1003777.
68. Shimizu I & Minamino T (2016). Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol 97, 245–262.
69. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS & Walsh K (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115, 2108–2118.
70. Simone NL, Soule BP, Ly D, Saleh AD, Savage JE, Degraff W, Cook J, Harris CC, Gius D & Mitchell JB (2009). Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One 4, e6377.
71. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM & Wang DZ (2007). Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42, 1137–1141.
72. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J & Engelhardt S (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signaling in fibroblasts. Nature 456, 980–984.
73. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, Van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G & Bauersachs J (2007). MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116, 258–267.
74. Topkara VK, Evans S, Zhang W, Epelman S, Staloch L, Barger PM & Mann DL (2011). Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol 51, 594–599.
75. Tu Y, Wan L, Bu L, Zhao D, Dong D, Huang T, Cheng Z & Shen B (2013). MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: A new mechanism for antihypertrophic intervention. Cell Physiol Biochem 31, 997–1008.
76. Ucar A Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K & Thum T (2012). The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3, 1078.
77. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ & Lötvall JO (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9, 654–659.
78. Valiente-Alandi I, Schafer AE & Blaxall BC (2016). Extracellular matrix-mediated cellular communication in the heart. J Mol Cell Cardiol 91, 228–237.
79. Varrone F, Gargano B, Carullo P, Di Silvestre D, De Palma A, Grasso L, Di Somma C, Mauri P, Benazzi L, Franzone A, Jotti GS, Bang ML, Esposito G, Colao A, Condorelli G & Catalucci D (2013). The circulating level of FABP3 is an indirect biomarker of microRNA-1. J Am Coll Cardiol 61, 88–95.
80. Viereck J Kumarswamy R, Foinquinos A, Xiao K, Avramopoulos P, Kunz M, Dittrich M, Maetzig T, Zimmer K, Remke J, Just A, Fendrich J, Scherf K, Bolesani E, Schambach A, Weidemann F, Zweigerdt R, de Windt LJ, Engelhardt S, Dandekar T, Batkai S & Thum T (2016). Long noncoding RNA Chast promotes cardiac remodelling. Sci Transl Med 8, 326ra22.
81. Waldenström A, Gennebäck N, Hellman U & Ronquist G (2012). Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells. PLoS One 7, e34653.
82. Wang G-K, Zhu J-Q, Zhang J-T, Li Q, Li Y, He J, Qin Y-W & Jing Q (2010). Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31, 659–666.
83. Wang J, Song Y, Zhang Y, Xiao H, Sun Q, Hou N, Guo S, Wang Y, Fan K, Zhan D, Zha L, Cao Y, Li Z, Cheng X, Zhang Y & Yang X (2012). Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice. Cell Res 22, 516–527.
84. Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, Liu CY, Sun T, Zhang XJ & Li PF (2014a). The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 114, 1377–1388.
85. Wang K, Long B, Zhou L-Y, Liu F, Zhou Q-Y, Liu C-Y, Fan Y-Y & Li P-F (2014b). CARL lncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun 5, 3596.
86. Wilusz JE & Sharp PA (2013). A circuitous route to noncoding RNA. Science 340, 440–441.
87. Xu XD, Song XW, Li Q, Wang GK, Jing Q & Qin YW (2012). Attenuation of microRNA-22 derepressed PTEN to effectively protect rat cardiomyocytes from hypertrophy. J Cell Physiol 227, 1391–1398.
88. Yang K-C, Yamada KA, Patel AY, Topkara VK, George I, Cheema FH, Ewald GA, Mann DL & Nerbonne JM (2014). Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodelling with mechanical circulatory support. Circulation 129, 1009–1021.
89. Yang Y, Ago T, Zhai P, Abdellatif M & Sadoshima J (2011). Thioredoxin 1 negatively regulates angiotensin II-induced cardiac hypertrophy through upregulation of miR-98/let-7. Circ Res 108, 305–313.
90. Yang Z, Cappello T & Wang L (2015). Emerging role of microRNAs in lipid metabolism. Acta Pharm Sin B 5, 145–150.
91. Zhang Y, Huang X-R, Wei L-H, Chung AC, Yu C-M & Lan H-Y (2014). miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther 22, 974–985.
92. Ziaeian B & Fonarow GC (2016). Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13, 1–11.